Pharma BD Deal Intelligence
ILEX gave Genzyme a real oncology franchise and, eventually, Lemtrada — but the MS blockbuster bet undershot its own hype and hit safety-driven decline within a decade of launch.
Full analysis, sources & comparables →This transaction is a very good strategic fit for Genzyme that provides us with a solid franchise in the important field of oncology... the foundation for a…
The FTC conditionally cleared Genzyme's $1 billion acquisition of ILEX Oncology, requiring divestiture of Campath rights for solid-organ-transplant acute…
ILEX had taken Campath through approval in 2001 for fludarabine-refractory CLL; Genzyme acquired ILEX in 2004 to access alemtuzumab and later repositioned the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Stock-for-stock; San Antonio TX; Campath/alemtuzumab; FTC required Schering AG divestiture for SOT use
ILEX gave Genzyme a real oncology franchise and, eventually, Lemtrada — but the MS blockbuster bet undershot its own hype and hit safety-driven decline within a decade of launch.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / ILEX Oncology Inc. (this deal) | 2004 | $1.0B | 66 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Genzyme Corporation / Biomatrix Inc. | 2000 | $700M | 65 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. | 2001 | $138M | 54 |
| Genzyme Corporation / Verigen AG | 2005 | $50M | 29 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
← Browse all deals · How we score deals
More: 2004 deals · Genzyme Corporation deals